Nocion's Phase 2b cough trial nears data after two completion-date pushes
ASPIRE's placebo-controlled readout will test whether taplucainium cuts cough frequency, the first efficacy signal for Nocion's sensory-neuron blocker class in this indication.
Executive Summary
- Nocion Therapeutics is heading toward a placebo-controlled Phase 2b readout that will show whether its inhaled sensory-neuron blocker reduces cough frequency in a population with no new approved treatment option in decades.
- The trial finished enrolling to its full target and moved to a closed-enrollment status, a normal progression toward readout rather than a sign of trouble.
- Chronic cough has drawn a wide field of small-molecule mechanisms tested and mostly discontinued, and taplucainium's specific target sits outside that group, so the trial has no direct mechanistic precedent to benchmark against.
- The trial's primary completion date moved twice since initial registration, and the readout window the sponsor guided to now sits after that most recent completion date, a sequencing worth watching rather than a delay in itself.
The trial
ASPIRE (NCT06504446) is a Phase 2b, placebo-controlled trial of taplucainium, an inhaled small molecule in the class Nocion calls charged sodium channel blockers, designed to selectively silence activated sensory nerve fibers implicated in chronic cough. The trial enrolled 455 adults with refractory or unexplained chronic cough lasting 12 months or longer across the United States, Canada, Germany, Poland, the United Kingdom, and Belgium. It randomized patients across three experimental arms and one placebo arm, with the primary endpoint defined as change in 24-hour cough frequency, measured in coughs per hour, from baseline. Nocion's Chief Executive Officer Richard Batycky said the company is "well-positioned to define a new standard of care in refractory and unexplained chronic cough" as it approaches the readout. NCT06504446+1Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446Nocion Therapeutics Appoints Vineet Agarwal as Chief Business OfficerMay 27, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The stake
Chronic cough affects an estimated 27 million adults in the United States, of whom about 9 million have the refractory or unexplained form the trial targets, and Nocion says no new therapy has been approved for the condition in the U.S. in 65 years. The current standard is off-label treatment the company describes as often inadequate. A placebo-controlled, randomized design with an objective cough-count endpoint, rather than a symptom scale alone, is built to produce a decision-grade signal on whether the mechanism actually suppresses cough. NocionNocion Therapeutics Appoints Vineet Agarwal as Chief Business OfficerMay 27, 2026
Enrollment and timing
The trial's enrollment target rose from 240 to 325 in August 2024 and then to 455 in August 2025, changes that predate the current, fully enrolled trial and reflect design finalization rather than a late-stage cut. The trial moved to Active, not recruiting status on June 11, 2026, the same day its primary completion date was revised to June 15, 2026, from an earlier April 10, 2026 estimate, which itself had been pushed from a November 2025 date set at trial start. Enrollment held flat against its 455-patient target through the most recent registry update, consistent with a trial that finished recruiting on plan rather than one that scaled back. NCT06504446Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446
The window
Nocion's May 27, 2026 disclosure guided to topline data in "early August," placing the stated readout window after the trial's own June 15, 2026 primary completion date, which is the ordinary sequence of database lock and analysis following a trial's last patient visit. The company separately disclosed full enrollment and guided to topline data in the third quarter of 2026, consistent with the August window. Nocion is also scheduled to present a poster on the ASPIRE study status at the ERS Cough Conference in July 2026, ahead of the topline data disclosure. Nocion+1Nocion Therapeutics Appoints Vineet Agarwal as Chief Business OfficerMay 27, 2026Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446
The competitive field
Chronic cough has been tested with a wide range of small-molecule mechanisms, including P2X3 antagonists gefapixant and camlipixant, the NK1 antagonist orvepitant, and other candidates targeting TRPV1, TRPA1, and NMDA receptors, none of which share taplucainium's target. That leaves the trial without a direct mechanistic comparator in the indication; the nearest precedents are modality matches only, small molecules tested against the same disease rather than the same biological target. The absence of a target-sharing competitor means the readout will be judged against the disease's unmet-need bar rather than against a rival program's disclosed effect size.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.